Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that focuses on the development of RNA interference (RNAi) therapeutics. These therapeutics are designed to silence specific genes associated with various diseases. Alnylam's innovative approach places it in a competitive landscape alongside companies like BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Sarepta Therapeutics, and Agios Pharmaceuticals.
In evaluating Alnylam's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are key metrics. Alnylam boasts a ROIC of 13.74% and a WACC of 5.69%, resulting in a ROIC to WACC ratio of 2.42. This indicates that Alnylam is generating returns well above its cost of capital, showcasing effective capital utilization.
Comparatively, Ionis Pharmaceuticals, with a ROIC of -9.98% and a WACC of 5.25%, has a ROIC to WACC ratio of -1.90, indicating negative returns relative to its capital costs. Sarepta Therapeutics and Agios Pharmaceuticals also show negative ROIC to WACC ratios, with -1.04 and -4.91 respectively. Sarepta's ROIC is -4.92% against a WACC of 4.73%, while Agios has a ROIC of -38.18% and a WACC of 7.78%. These figures highlight challenges in generating positive returns on invested capital for these companies.
Alnylam's superior ROIC to WACC ratio of 2.42 positions it as a leader in capital efficiency among its peers. This suggests that Alnylam is effectively utilizing its capital to generate returns, making it a potentially attractive investment compared to its peers.
